CN1496737A - Method for treating inflammation of muscular skeleton and connective tissue - Google Patents
Method for treating inflammation of muscular skeleton and connective tissue Download PDFInfo
- Publication number
- CN1496737A CN1496737A CNA2003101017637A CN200310101763A CN1496737A CN 1496737 A CN1496737 A CN 1496737A CN A2003101017637 A CNA2003101017637 A CN A2003101017637A CN 200310101763 A CN200310101763 A CN 200310101763A CN 1496737 A CN1496737 A CN 1496737A
- Authority
- CN
- China
- Prior art keywords
- treatment
- purposes
- cis
- patient
- ict
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title abstract description 21
- 206010061218 Inflammation Diseases 0.000 title abstract description 16
- 230000004054 inflammatory process Effects 0.000 title abstract description 16
- 210000002808 connective tissue Anatomy 0.000 title description 2
- 230000003387 muscular Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 claims abstract description 59
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims abstract description 45
- 229960005280 isotretinoin Drugs 0.000 claims abstract description 45
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 33
- 206010034464 Periarthritis Diseases 0.000 claims abstract description 26
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract description 17
- 238000012423 maintenance Methods 0.000 claims abstract description 17
- 208000000491 Tendinopathy Diseases 0.000 claims abstract description 16
- 206010043255 Tendonitis Diseases 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 201000004415 tendinitis Diseases 0.000 claims abstract description 16
- 210000003205 muscle Anatomy 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 20
- 230000037396 body weight Effects 0.000 claims description 10
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 10
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 5
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 5
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 5
- 229960004544 cortisone Drugs 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000000554 physical therapy Methods 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 206010057254 Connective tissue inflammation Diseases 0.000 abstract 1
- 238000011283 initial treatment period Methods 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 201000010099 disease Diseases 0.000 description 15
- 230000003203 everyday effect Effects 0.000 description 10
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 210000002435 tendon Anatomy 0.000 description 8
- 230000036285 pathological change Effects 0.000 description 7
- 231100000915 pathological change Toxicity 0.000 description 7
- 210000000845 cartilage Anatomy 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 210000001217 buttock Anatomy 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 210000000513 rotator cuff Anatomy 0.000 description 4
- 238000007086 side reaction Methods 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 3
- 208000007613 Shoulder Pain Diseases 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229940059329 chondroitin sulfate Drugs 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 150000002337 glycosamines Chemical class 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000000281 joint capsule Anatomy 0.000 description 3
- 229940072709 motrin Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 208000008822 Ankylosis Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 201000011275 Epicondylitis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 206010023198 Joint ankylosis Diseases 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000002240 Tennis Elbow Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048049 Wrist fracture Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940013181 advil Drugs 0.000 description 1
- 229940060515 aleve Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000010588 calcific tendinitis Diseases 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229940090008 naprosyn Drugs 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000426 patellar ligament Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000000029 referred pain Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000462 teratogen Toxicity 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A method of treating said musculoskeletal and connective tissue inflammations including osteoarthritis and associated articular and periarticular inflammations, and non-articular Rheumatism including capsulitis, tendonitis, fibrositis, and perarticular inflammations is disclosed. The method includes administering to a patient of a therapeutically effective amount of a composition comprising 13-cis-retinoic acid. Preferably, the treatment method includes administering to a patient of an initial dosage of a composition comprising 13-cis-retinoic acid for an initial treatment period, and thereafter administering a maintenance dosage of the composition.
Description
Technical field
The present invention relates to a kind of method for the treatment of muscle skeleton and ICT.More particularly, this method is used the 13-cis-retinoic acid and is treated muscle skeleton and ICT effectively, this muscle skeleton comprises osteoarthritis and joint and the periarthritis disease relevant with osteoarthritis with ICT, and nonarticular rheumatism, nonarticular rheumatism comprises capsulitis, tendinitis, fibrositis and periarthritis disease.
Background technology
Muscle skeleton and ICT are a large amount of crowds' of infringement common diseases.Some common muscle skeletons comprise osteoarthritis and joint and the periarthritis disease relevant with osteoarthritis with ICT, and nonarticular rheumatism, and nonarticular rheumatism comprises capsulitis, tendinitis, fibrositis and periarthritis disease.
Osteoarthritis is a kind of the most common arthritis type, is more common in the old people.Osteoarthritis is a kind of joint disease of main invasion and attack cartilage.Cartilage is the smooth tissue that intraarticular covers epiphysis.Healthy cartilage can make skeleton slide mutually freely, the energy that vibrations are produced in the time of also can the absorbing bodily motion.When osteoarthritis takes place when, the top layer disintegrate wearing and tearing of cartilage.This makes and the mutual friction of subchondral skeleton phase causes pain, swelling and joint movement disorder.As time goes on, the joint will be out of shape.In addition, also can grow bony spur at the edge in joint.Fritter bone or cartilage can come off, and float in the joint space.This can cause more serious pain and damage.The people who suffers from osteoarthritis generally has the symptom of arthralgia and limitation of activity.Different with the arthritis of other types is that osteoarthritis is only encroached on the joint, and does not encroach on the internal.
Osteoarthritis is one of common cause that causes adult's physical disabilities.In the U.S., there are more than 2,000 ten thousand people may suffer from this disease.Some youngsters are suffered from osteoarthritis owing to the joint is injured, but osteoarthritis mainly betides the old people.In fact, in the crowd below 65 years old, at least one joint that surpasses the people of half suffers from the osteoarthritis of making a definite diagnosis through X-ray.Because U.S. old people's number is in continuous increase, so osteoarthritis patient's number also is constantly to increase.The men and women all can suffer from this disease.
The measure of treatment osteoarthritis at present comprises exercise, endo-medicine, rest, joint maintenance, surgical operation, pain relief technology, alternative medicine and controlling body weight etc.The medicine of treatment osteoarthritis commonly used comprises nonsteroidal anti-inflammatory agent (NSAIDs), as aspirin, Advil
(ibuprofen), Motrin
IB (ibuprofen), Aleve
(naproxen sodium), ketoprofen; The local pain that directly applies to skin is alleviated Emulsion, wiping agent and spray (as capsaicin Emulsion); Cortical steroid, a kind of natural in vivo synthetic or as the powerful antiinflammatory hormone of medicine synthetic, be injected into usually and encroached on the joint, with respite pain; And hyaluronic acid, a kind of novel drugs that is used for joint injection is used for the treatment of the knee osteoarthritis.Adopt surgical operation can reproduce (polishing) surface of bone, restore skeleton and joint replacement.For some patients, surgical operation helps to alleviate pain and the deformity due to the osteoarthritis.Osteoarthritis is a kind of chronic disease, although multiple medicine has been used for the treatment of this disease, this is not effective aspect sick to these medicines in long-term control and prevention.
A kind of most common form of capsulitis is an adhesive capsulitis, is also referred to as " congealed shoulder ", and the pain of this disease can cause the movable serious forfeiture of shoulder.Its symptom mainly is that pain and the range of motion that the serious inflammation by joint capsule causes dwindles.When motion reached the limit of range of activity, shoulder was understood pain usually, and the aggravation at night.The reason of this disease is not also understood now.There is a kind of theory to think what autoimmune response caused.Adhesive capsulitis can be secondary to other damages, and these damages make the shoulder can not normal activity.After a common example is wrist fractures, may need to place sling to reach several weeks arm, so just limit the activity of shoulder.In addition, when other shoulder illness occurring, " congealed shoulder " also can take place.Sometimes, problem such as tear such as bursitis, bump syndrome or local rotator cuff and also can cause congealed shoulder.
Usually, before solving basic problem, must at first treat adhesive capsulitis to recover the shoulder activity.The treatment of congealed shoulder may baffle or slowly.Initial treatment also can be used anti-inflammatory drug at reducing inflammation and adopting the stretching, extension scheme to increase the shoulder range of activity.Startup and lasting physiotherapy also are important to recover the shoulder activity.Injection cortisone and long-acting anesthetis also can control inflammation preferably, and make the stretching, extension therapeutic scheme more effective.Most of cases finally can improve.But generally, the range of activity of shoulder can not recovered fully.
Tendinitis be with tendon on the skeleton adhere to the place pain be a kind of inflammation of feature.The tendinitis predilection site comprises shoulder rotator cuff (spinal column and biceps tendon); Wrist extensor (lateral epicondylitis and tennis) and ancon musculus flexor (middle epicondylitis) adhere to the place; The ilium shin band of patellar ligament, state portion tendon and knee; Shank ossa tibiale posterius tendon adhere to place's (outer shin inflammation); The heel string of heel.Tendinitis is caused by excessive use mostly.Usually can observe the pathological change that conforms to chronic inflammatory disease.Also can observe with the cellular atrophy is the tissue degeneratiaon of feature.Calcium salt can precipitate (as calcific tendinitis) along the direction of tendon, and shoulder is modal site of pathological change.Chronic tendinitis can cause tendon to die down and the Secondary cases fracture.Middle age is the most responsive to the development of tendinitis.
The purpose of Drug therapy tendinitis is pain management and reduces inflammation.Existing treatment measure comprises nonsteroidal anti-inflammatory agent (NSAIDs), splinting or fixation; And the lignocaine/steroid injection around the tendon.Non-steroidal antiinflammatory drugs comprises ibuprofen, flurbiprofen, naproxen, mefenamic acid, ketoprofen, indometacin and piroxicam.
Fibrositis is a kind of more common nonarticular rheumatism.It may be partial or disperse that fiber is knitted class.The dispersivity fibrositis that occurs in a plurality of positions of health is also referred to as fibromyalgia.Fibrositis is and muscle and the disease that contiguous connective tissue is touched a tender spot, pain is relevant that it shows as the pain at fibrous tissue, muscle, tendon, ligament and other position with fibromyalgia.Any fibrillar muscle is organized all effected, but the fibrillar muscle of occipitalia, cervical region, shoulder, chest, back and thigh organize be subject to especially the infringement.For fibromyalgia, can discern " trigger point " that different focuses are touched a tender spot, and General Symptoms can often occur also as fatigue, insomnia and depression.
The pain of fibrositis and sore spot feature are attributable to Several Factors.At first, the local inflammation that may exist virus to cause.This as the back or cervical region got flu.The myalgia of general is to be caused by the general toxin in the blood due to the viral infection, and this viral infection also can betide other position usually except the muscle or joint capsule place that occur in pain.In addition, a common cause of local trigger point formation is so-called " referred pain ".Is by wound in the many joints that link to each other with spinal column as the strain or the common site of spraining the inflammation that causes.Because these joints are near the nerve sheath of the nerve that spreads out from spinal cord, these nerve sheath that are called as " dura mater " can be upset and pain or be inflamed.When these pathological changes took place, problem did not just lie in and has been subjected to infringement place, but is deep in the inflammation intraarticular and nerve sheath.If pain and tenderness continue a plurality of months, will cause chronic pain and ankylosis.Above-mentioned mechanism can occur in a plurality of different parts of health.Ancon, heel, back, cervical region and the shoulder relevant with the painful trigger point is common site of pathological change.The existing measure of treatment fibrositis comprises cortisone injection, nonsteroidal anti-inflammatory agent (NSAIDs) and physiotherapy.For fibromyalgia, the treatment measure comprises that the tricyclic antidepressants, exercise and the oneself that are used for relaxed muscle and improve sleep quality loosen.
Many muscle skeletons and ICT are chronic, and can cause the afunction of chronic local pain and affected areas.These diseases are patient harm from the health not only, and influences their economy and life style.Economic implication comprises that medical expense and the disabled salary that causes descend.To the influence of life style comprise that depression, anxiety, helplessness, daily routines are limited, work limit, daily family is happy and the forfeiture of responsibility.
Sell by the Hoffmann-La Roch company of New Jersey nanotesla profit, trade mark is Accutane
The 13-cis-retinoic acid, be that usually said tretinoin is also referred to as Accutane, described 13-cis-retinoic acid is as the dermatological medicament of part or oral application, and is long ago just known, and this medicament can be used for treating acne vulgaris and other several dermatosiss.The 13-cis-retinoic acid can suppress the effect and the keratinization of sebaceous gland.Accutane
The definite mechanism of action of treatment acne is not also understood.Because tretinoin is a kind of teratogen, and the relevant mutagenesis of medicine is therewith arranged, so it only is used for the treatment of the invalid serious acne of additive method.
Since 1992, occurred about the bibliographical information of 13-cis-retinoic acid to the latent effect of Human Prostate Cancer Cells.U.S. Patent number 5,612,354 (Sanzet etc.) have disclosed the method that a kind of treatment suffers from hyperplasia and is divided into the mammalian diseases of feature unusually, and this method comprises that by the quinoline that (the 1H-pyrroles-1-ylmethyl) of mammal whole body or local application effective dose replaced the 13-cis-retinoic acid treats.Because the quinoline that (1H-pyrroles-1-ylmethyl) replaces has the ability that postpones retinoic acid metabolism, so be considered to be used for the treatment of acne.
As mentioned above, obviously, the medicine that can treat muscle skeleton and ICT is effectively still had very big demand.The medicine of a kind of energy long-term control muscle skeleton and ICT, the existing disease progression of inhibition and prophylaxis of acute symptomatic recurrence has the important medical meaning for millions upon millions of patients that suffer from described disease.
Summary of the invention
In one embodiment, the present invention relates to a kind of method for the treatment of muscle skeleton and ICT.Described inflammation comprises osteoarthritis and joint and the periarthritis disease relevant with osteoarthritis, and nonarticular rheumatism, and described nonarticular rheumatism comprises capsulitis, tendinitis, fibrositis and periarthritis disease.Described method comprises that the compositions that contains the 13-cis-retinoic acid with effective therapeutic dose is applied to the patient.Described compositions also contains pharmaceutical carrier, and can powder, the form of pill, capsule, tablet and liquid exists.Under the preferred situation, the method for described treatment muscle skeleton and ICT comprises the steps: to use described compositions preliminary dosage, that contain the 13-cis-retinoic acid in the preliminary treatment phase to the patient; Subsequently, to the patient use maintenance dose contain the 13-cis-retinoic acid described compositions, described muscle skeleton comprises osteoarthritis and joint and the periarthritis disease relevant with osteoarthritis with ICT, and nonarticular rheumatism, described nonarticular rheumatism comprises capsulitis, tendinitis, fibrositis and periarthritis disease.
In another embodiment, the present invention relates to a kind of osteoarthritis for the treatment of and reach the joint relevant with osteoarthritis and the combined method of periarthritis disease and nonarticular rheumatism, described nonarticular rheumatism comprises capsulitis, tendinitis, fibrositis and periarthritis disease.Described combination therapy has adopted the traditional method of treatment muscle skeleton and ICT, and uses compositions effective therapeutic dose, that contain the 13-cis-retinoic acid to the patient.
So, the purpose of this invention is to provide treatment muscle skeleton and ICT and a kind of medicine of associated symptom.
By hereinafter the statement the specific embodiment and additional claim as can be known, the above and other objects and advantages of the present invention are conspicuous.
The specific embodiment
In one embodiment, the present invention relates to a kind of method for the treatment of muscle skeleton and ICT.The muscle skeleton that is suitable for comprises osteoarthritis and joint and the periarthritis disease relevant with osteoarthritis without limitation with the ICT type, and the nonarticular rheumatism that comprises capsulitis, tendinitis, fibrositis and periarthritis disease.Described method comprises to the patient uses a kind of compositions effective therapeutic dose, that contain the 13-cis-retinoic acid.The scope of described effective therapeutic dose is daily to take in about 80 milligrams of the about 10-of 13-cis-retinoic acid (about 1.1 milligrams of the about 0.14-of every kg body weight).
Described compositions also contains pharmaceutical carrier.Common pharmaceutical carrier comprises liquid carrier, as the analog of oral liquids such as water, ethylene glycol, oil, ethanol, syrup and suspension, syrup, elixir and solution; Solid carrier is as analog such as starch, saccharide, Kaolin, lubricant, binding agent, disintegrating agent and powder, pill, capsule and tablets; Other pharmaceutical carriers well known in the art.The compositions that is used for purpose of the present invention can exist with various form, as powder, pill, capsule, tablet and medicinal liquid etc.Although because of its convenience preferred oral preparation, be to use other suitable general administering modes also to can be used for purpose of the present invention.
The 13-cis-retinoic acid is a kind of commercial medicine, and its trade mark is Accutane
, produce by the sharp Hoffmann-La Roche of New Jersey nanotesla company, be used for the treatment of some dermatosis.Accutane
Three kinds of available dosage forms are arranged, the Perle of promptly 10 milligrams, 20 milligrams and 40 milligrams.
Preferred Therapeutic Method comprises two treatment phases: tentatively treat the phase and keep the treatment phase.At first, in preliminary treatment, the patient takes the 13-cis-retinoic acid of preliminary dosage, about 10 days to about 5 months its medicine time.Subsequently, this patient takes the 13-cis-retinoic acid of lower maintenance dose.
The preferred preliminary treatment phase is about 2-3 week because as surpass 2-3 week, some side effect of this medicine, as tenderness, xerosis cutis, the lip of fiber-muscle-old injury of skeleton system chap, eyes are dry and astringent and nose drying etc. will take place.If tentatively these side effect appear in the treatment phase, then after beginning to take maintenance dose, described side effect can weaken usually.If but side effect does not appear in the patient, then can prolong the preliminary treatment phase, to strengthen the effect of this medicine treatment muscle skeleton and ICT.But in 20 weeks of continuous administration when the 13-cis-retinoic acid is used for the treatment of the patient who suffers from serious acne at present, based on this, according to the individual patients reaction and the state of an illness, the preliminary treatment phase of the present invention can be longer than several weeks basically.
Low keep dosage two functions are arranged.At first, after the preliminary treatment, the treatment of using maintenance dose needs several time-of-weeks to control existing muscle skeleton and ICT, and the existing inflammation disease of inhibition further develops deterioration.The second, the long term maintenance dosed administration can prevent the recurrence of muscle skeleton and ICT, and described inflammation is clinically often with various chronic muscle skeletons and ICT.Under the therefore preferred situation, answer the chronic administration maintenance dose.
Dosage should be decided according to patient's body weight.Preliminary dosage is the 13-cis-retinoic acid (about 1.1 milligrams of the about 0.14-of every kg body weight) of about 10-80 milligram every day.For body weight is the ordinary people of 160 pounds (72.6 kilograms) approximately, and average preliminary dosage is about 40 milligrams of every day.Maintenance dose was to take the about 10-80 milligram of 13-cis-retinoic acid (about 1.1 milligrams of the about 0.14-of every kg body weight) every 3-7 days.For body weight approximately is 160 pounds ordinary people, average maintenance dose be every 3-7 days about 40 milligrams.Be starkly lower than or be higher than the people of average weight for child or body weight, should correspondingly adjust its dosage.
Patient's dosage every day can be taken disposable or in batches.Because Accutane
The i.e. Perle of 10 milligrams, 20 milligrams and 40 milligrams of three kinds of commercial dosage forms is arranged, so, take one 40 milligrams capsule every day but preliminary dosage is 40 milligrams patient, or take two 20 milligrams capsule every day, or take 4 10 milligrams capsule every day.The dosage of keeping treatment is the same.For simplicity, during keeping treatment, the patient took 40 milligrams dosage in every approximately 3-7 days one time.
Have now found that, use method of the present invention to treat after, the state of an illness that the patient who suffers from muscle skeleton and ICT after diagnosing obtains is in various degree improved.Visible improvement comprises and having alleviated because of for example muscle skeleton of affected body parts such as cervical vertebra, shoulder, hands, buttocks and neck and pain and the tenderness that ICT causes; Alleviate arthroncus; Eliminate the other fibrocalcific tuberosity of cervical vertebra vertebra; Alleviate ankylosis and enlarge range of activity; Recover physical ability.In addition, use above-mentioned Therapeutic Method, do not observe serious adverse.
Clinical effectiveness based on this medicine, think now, the 13-cis-retinoic acid can be controlled muscle skeleton and ICT, eliminate and reinvent joint and the periarticular pathological changes that causes by described disease, comprising: it is plump and eliminate the bone fibres cartilage lesion of peripheral region, joint to decompose ligament and joint capsule, and reinvents the pathological changes that described disease causes and make it to be tending towards more normal structure.The detailed mechanism of 13-cis-retinoic acid treatment muscle skeleton and ICT still belongs to unknown at present.
Importantly, have been found that now by secular hanging down and keep dosed administration, the 13-cis-retinoic acid can provide the long-term control to muscle skeleton and ICT, suppress existing inflammation disease and further worsen, and prevent the acute relapse of described chronic muscle skeleton and ICT.Consider that the number of suffering from this type of common chronic disease is more, and the forfeiture of health natural functions can occur lack effectively long-term prevention of described disease and control, so the present invention to have the important medical meaning with PD in addition.
In another embodiment, method of the present invention can be used as the ancillary method of other traditional therapies that are used for the treatment of muscle skeleton and ICT.Described traditional method comprises cortisone injection, surgical operation therapy, uses nonsteroidal anti-inflammatory agent and physiotherapy to general.Using of the 13-cis-retinoic acid of effective dose can be used for auxiliary other traditional remedies, and can be used for improving overall therapeutic effect.Using the 13-cis-retinoic acid can carry out simultaneously with traditional remedies, for example carries out with cortisone or hyaluronic acid injection; Use with conventional medicaments such as nonsteroidal anti-inflammatory agent, chondroitin sulfate and glycosamines; Or carry out with physiotherapy.13-cis-retinoic acid therapy of the present invention also can be carried out before operation or after the operation.
Embodiment 1 to embodiment 3 for example understands the clinical effectiveness of above-mentioned Therapeutic Method.Write out a prescription to the patient and to carry out preliminary treatment recited above and to keep treatment.It should be noted that the weight in patients described in the example all in the average weight scope, therefore, has adopted 40 milligrams mean dose.Should also be noted that because take Accutane
Can cause photosensitivity, so, enjoined all patients to avoid sun exposure fully in the preliminary treatment phase with in last or two weeks after keeping the treatment beginning.
Embodiment 1:
1988, white race male patient's joint disease outbreak that 62 years old, health are roughly healthy, its affected part only is a hand.Main site of pathological change is once in the tip interphalangeal joint (IP joint) of fracture in 1980.Symptom has edema and swelling, with the tenderness of aggravation year by year.This tenderness is more and more obvious, to such an extent as in 1994, this patient can not wave because of pain.In addition, because finger swelling and tightening, the carrying out property obstacle of clenching fist appears in the patient.
X-ray examination finds that articular cavity attenuates and the interphalangeal joint capsular swelling.The lab testing result is normal.The patient is suffered from osteoarthritis companion tendinitis by diagnosis.
Atomic or absolutely void at several treatment measure effects that this patient adopts, these treatment measures comprise aspirin (every day 2-5 grain 325 milligrams pill); Motrin
TM(ibuprofen) and Naprosyn
TM(naproxen); And glycosamine/chondroitin sulfate.
In April, 1997, because of another disease, this patient begins to take Accutane
(13-cis-retinoic acid, Hoffmann-La Roche company, nanotesla profit, New Jersey), preliminary dosage is about 40 milligrams Accutane every day
, continue 21 days, then a week 2 times (Monday and Fridays) is taken about 40 milligrams maintenance dose.In some months subsequently, the patient notices that its hand state of an illness obtains progressively, stable improvement, and the stiff and pain of the shoulder that is caused by the right side old wound of shoulder rotator cuff also is improved.In addition, the patient is also noted that its cervical vertebra touches a tender spot and also slowly improve (be subjected to serious whiplash in the nineteen sixty-eight traffic accident after, its cervical vertebra touch a tender spot last very long), and with the expansion and the other fibrocalcific nodular elimination of cervical vertebra vertebra of range of activity (ROM).
Because patient's osteoarthritis and tendinitis are able to obvious improvement, the patient continues the Accutane of above-mentioned maintenance dose
Treatment so far.Except occurring side effect such as lip, chapped skin in early days, other health side effect do not appear.In the preliminary treatment phase, notice the right shoulder pain that principal characteristic once occurs adding, but disappeared afterwards.Blood samples of patients is biochemical and the hematological examination result is normal always.
This patient's whole health is improved greatly, and the weak disease of any never again muscle skeleton occurs.
Embodiment 2:
69 years old, the retired warrant officer of naval, white race male old man are suffered from struvite osteoarthritis and rheumatism by diagnosis.Its symptom comprises the arthralgia that continues 6-10.In 1992, the right buttocks of arthralgia invasion and attack patient was subjected to the torment of pain of buttock deeply when the patient works at first.1994, cervical region and left shoulder pain progressively appearred in the patient.The X-ray examination result shows the cervical vertebra calcification.In addition, patient's shoulder is suffered from the rotator cuff wound by diagnosis.1997, touching a tender spot appearred in patient's hand when playing golf.After this patient's hand state of an illness further worsens, and the floating bloated and difficulty of clenching fist of finger occurs.But patient's blood biochemical is normal.
The patient adopted aspirin and Motrin in the past
TMTreatment, but have little effect.And have only of short duration effect with glycosamine/chondroitin sulfate extract for treating.Naturopathy just part has been alleviated the hand state of an illness.Because the hand swing and the difficulty of clenching fist, the patient worry can not such as own institute hopes often be engaged in golf sports, even be forced to consideration and abandon this motion.
This patient adopts the treatment of 13-cis-retinoic acid on May 1st, 2002, and preliminary dosage is about 40 milligrams of Accutane every day
, continue 14 days, then week 2 times is used about 40 milligrams maintenance dose to the patient.After the treatment through 7 weeks altogether, patient's shoulder pain complete obiteration (annotate: in the 13-cis-retinoic acid treatment phase, the patient continues naturopathy is carried out in this zone), it is normal that range of activity is recovered, cervical region and pain of buttock almost completely disappear (ending in August, 2002).Under situation about playing golf continuously 3-4 days, patient's hand still has slight tenderness.But the floating the symptom bloated and difficulty of clenching fist of hand has disappeared.Because health is significantly improved, patient's golf obstacle rank drops to 9 by 11.
After the patient takes the 13-cis-retinoic acid, have only slight side reaction, what comprise former of dry and some left shoulders of skin, lip adds principal characteristic pain, and these side reactions had disappeared afterwards.
Embodiment 3:
A white race male peasant of 61 years old has the pain in hand history that relates to finger in more than 10 year, with interphalangeal joint swelling and tenderness.The hand illness makes its work and the difficulty that plays golf.He is suffered from osteoarthritis by diagnosis.
This patient begins to carry out the treatment of 13-cis-retinoic acid April calendar year 2001, preliminary dosage about 400 milligrams of Accutane every day
, continuing 21 days, week 2 times is used about 40 milligrams maintenance dose to the patient subsequently.After treating for 10 weeks, patient's symptom begins to improve, and comprises the expansion with range of activity of alleviating of finger swelling and tenderness symptom.Follow-up 6 the middle of the month continuous administration maintenance dose, its doing well,improving is kept.
Patient's hematological results is all normal before and after treatment.Except skin and lip drying, the patient does not have other side reaction.These side reactions have disappeared behind the picked-up maintenance dose.
Though shown and described the preferred embodiments of the invention, should be understood that except the concrete embodiment that shows and describe herein, the present invention can also adopt other modes to implement here.And, in described embodiment, without prejudice to as the prerequisite of the basic thought of following additional claims of the present invention and principle under, can and arrange to do some change to the form of each several part.
Claims (10)
1. the compositions that comprises the 13-cis-retinoic acid is used for the treatment of purposes in the medicine of muscle skeleton and ICT in preparation.
2. purposes as claimed in claim 1, wherein said compositions also contains a kind of pharmaceutical carrier.
3. purposes as claimed in claim 2, the existence form of wherein said compositions is selected from the group of being made up of powder, pill, capsule, tablet and liquid.
4. purposes as claimed in claim 1, wherein said muscle skeleton comprises osteoarthritis and relevant arthritis and periarthritis disease with ICT, and nonarticular rheumatism, wherein said nonarticular rheumatism comprises capsulitis, tendinitis, fibrositis and periarthritis disease.
5. purposes as claimed in claim 1, wherein the treatment to described muscle skeleton and ICT comprises the preliminary treatment phase and keeps the treatment phase.
6. purposes as claimed in claim 5, wherein the preliminary dosage in the preliminary treatment phase is that per kg body weight per day is used about 0.14 milligram-Yue 1.1 milligrams of 13-cis-retinoic acids.
7. purposes as claimed in claim 5, the wherein said preliminary treatment phase is about 10 days to 5 months.
8. purposes as claimed in claim 5, wherein said compositions are that every 3-7 days every kg body weight are used about 0.14 milligram-Yue 1.1 milligrams of 13-cis-retinoic acids at the maintenance dose of keeping the treatment phase.
9. purposes as claimed in claim 1, wherein said treatment comprise with the traditional therapy of treatment muscle skeleton and ICT and are used in combination the compositions that comprises the 13-cis-retinoic acid.
10. purposes as claimed in claim 9, wherein said traditional therapy comprise cortisone injection, hyaluronic acid injection, surgical operation therapy, use nonsteroidal anti-inflammatory agent and physiotherapy to general.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2003101017637A CN1496737A (en) | 2002-10-23 | 2003-10-23 | Method for treating inflammation of muscular skeleton and connective tissue |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/278,706 | 2002-10-23 | ||
| CNA2003101017637A CN1496737A (en) | 2002-10-23 | 2003-10-23 | Method for treating inflammation of muscular skeleton and connective tissue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1496737A true CN1496737A (en) | 2004-05-19 |
Family
ID=34256624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2003101017637A Pending CN1496737A (en) | 2002-10-23 | 2003-10-23 | Method for treating inflammation of muscular skeleton and connective tissue |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1496737A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116546982A (en) * | 2020-05-24 | 2023-08-04 | 李兆阳 | Retinoic acid compositions and methods thereof |
-
2003
- 2003-10-23 CN CNA2003101017637A patent/CN1496737A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116546982A (en) * | 2020-05-24 | 2023-08-04 | 李兆阳 | Retinoic acid compositions and methods thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mellick et al. | Reflex sympathetic dystrophy treated with gabapentin | |
| JPS59502024A (en) | Rheumatic disease treatment agent | |
| US20170095539A1 (en) | Composition for Prevention and Treatment of Joint Pain and the Method of Preparation Thereof | |
| Bostan et al. | Comparison of intra-articular hyaluronic acid injections and mud-pack therapy in the treatment of knee osteoarthritis | |
| Montagna et al. | " Painful legs and moving toes" associated with polyneuropathy. | |
| Mellick et al. | The use of gabapentin in the treatment of reflex sympathetic dystrophy and a phobic disorder | |
| Leslie | Hyaluronic Acid Treatment for Osteoarthritis | |
| US7071228B2 (en) | Method of treating musculoskeletal and connective tissue inflammations | |
| CN1496737A (en) | Method for treating inflammation of muscular skeleton and connective tissue | |
| Koszowska et al. | Osteoarthritis–a multifactorial issue | |
| Arabelovic et al. | Considerations in the treatment of early osteoarthritis | |
| US4073897A (en) | Treatment of arthritis and allied conditions with xenylsalate | |
| Abbott et al. | A comparison of the efficacy of naproxen sodium and a paracetamol/dextropropoxyphene combination in the treatment of soft-tissue disorders. | |
| Fava et al. | Single Nightly Administration of Ketoprofen (Orudis®) and Indomethacin Suppositories in the Management of Osteoarthritis: A Double-Blind Trial | |
| GARTLAND et al. | Use of hyaluronidase in soft tissue injury and its influence on experimental bone repair | |
| Venkateswari et al. | Trigger finger: An integrated approach utilizing naturopathy and yoga interventions: A case study | |
| MUKKAMALA et al. | Physiotherapy Management of Musculoskeletal Disorders in Diabetes Mellitus-A Narrative Review. | |
| Khan | Homoeopathic rare remedies for osteoarthritis of knee joint | |
| Pei et al. | A randomized controlled trail on the treatment of knee osteoarthritis with acupotomy therapy based on the meridian sinew theory | |
| Calabro | Indomethacin in acute painful shoulder bursitis and/or tendinitis | |
| Postuma et al. | The intraarticular and periarticular use of corticosteroids in knee and shoulder | |
| SU1174032A1 (en) | Method of treatment of psoriatic arthropathy | |
| CN101518627A (en) | Drug for treating broken bones by fast reunion of muscles and bones | |
| Qi-ping et al. | Clinical observation on treatment of 60 cases of osteoarthritis of knee joint by electroacupuncture | |
| Reich | What is the Best Way to Combat the Symptoms of Knee Osteoarthritis? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |